Your SlideShare is downloading. ×
Liver Diseases Therapeutics Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Saving this for later?

Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime - even offline.

Text the download link to your phone

Standard text messaging rates apply

Liver Diseases Therapeutics Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018

332
views

Published on

This report covers the performance of the various drugs class segment used in liver disease therapeutics in terms of their revenue. The global market for liver diseases therapeutics is classified into …

This report covers the performance of the various drugs class segment used in liver disease therapeutics in terms of their revenue. The global market for liver diseases therapeutics is classified into seven drug class segments namely, anti-viral drugs, vaccines, immunosuppressants, immunoglobulins, targeted therapy, corticosteroids and chemotherapy with their estimated and forecasted market size from 2012 to 2018, along with their compound annual growth rate.
This report also covers an in-depth competitive analysis for the market, taking into consideration some of the major market players. The market players considered are: Abbott Laboratories, Astellas Pharma Inc, Gilead Science Inc., Merck & Co., Bristol-Myers Squibb, Novartis, Pfizer and Roche. A detailed analysis of their business strategies, company overview, financial overview, product portfolio and recent developments is also provided in the report.


Sourse:http://www.transparencymarketresearch.com/liver-diseases-therapeutics.html

Published in: Health & Medicine

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
332
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Transparency Market ResearchLiver Diseases Buy NowTherapeutics Market - Request SampleGlobal Industry Analysis,Size, Share, Trends And Published Date: Jan 2013Forecast, 2012 – 2018 Single User License: US $ 4595 112 Pages Report Multi User License: US $ 7595 Corporate User License: US $ 10595 REPORT DESCRIPTION Liver Diseases Therapeutics Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 – 2018 This report covers the performance of the various drugs class segment used in liver disease therapeutics in terms of their revenue. The global market for liver diseases therapeutics is classified into seven drug class segments namely, anti-viral drugs, vaccines, immunosuppressants, immunoglobulins, targeted therapy, corticosteroids and chemotherapy with their estimated and forecasted market size from 2012 to 2018, along with their compound annual growth rate. This report also covers an in-depth competitive analysis for the market, taking into consideration some of the major market players. The market players considered are: Abbott Laboratories, Astellas Pharma Inc, Gilead Science Inc., Merck & Co., Bristol-Myers Squibb, Novartis, Pfizer and Roche. A detailed analysis of their business strategies, company overview, financial overview, product portfolio and recent developments is also provided in the report.
  • 2. Browse Report: Liver Diseases Therapeutics MarketWe have used secondary research for deriving our market numbers for each segment of theresearch report and further validated our analysis with C-level executives of majorcompanies operating in liver diseases therapeutics market through the means of primaryresearch to finally come up with our results. This research is specially designed to estimateand analyze the performance of liver diseases therapeutics in a global scenario. Thisresearch provides in-depth analysis of liver diseases therapeutics market sales, trendanalysis by segments.TABLE OF CONTENTSCHAPTER 1 PREFACE1.1 REPORT DESCRIPTION1.2 RESEARCH METHODOLOGYCHAPTER 2 EXECUTIVE SUMMARYCHAPTER 3 MARKET OVERVIEW3.1 INTRODUCTION3.2 MARKET SIZE3.3 COMPARATIVE ANALYSIS OF GLOBAL LIVER DISEASES THERAPEUTICS MARKET, BYDRUG CLASS, 2011 & 20183.4 LIVER DISEASES THERAPEUTICS MARKET DYNAMICS 3.4.1 DRIVERS 3.4.1.1 Aging population inducing chronic liver diseases such as hepatitis andliver cancer 3.4.1.2 Increasing global prevalence of liver diseases 3.4.1.3 High unmet needs exist in the liver cancer therapeutics 3.4.1.4 Increased vaccination in emerging economies 3.4.2 LIVER DISEASE THERAPEUTICS MARKET DRIVERS IMPACT ANALYSIS 3.4.3 RESTRAINTS 3.4.3.1 Side-effects and risks
  • 3. 3.4.3.2 FDA approvals and other government regulations 3.4.3.3 Availability of alternate treatment procedures 3.4.4 LIVER DISEASE THERAPEUTICS MARKET RESTRAINTS IMPACT ANALYSIS 3.4.5 OPPORTUNITIES 3.4.5.1 Strong pipeline drugs 3.4.5.2 Emerging economies in Asia, Latin America and Eastern Europeancountries 3.4.5.3 Consolidation opportunities in the healthcare industry3.5 PORTER’S FIVE FORCES ANALYSIS FOR LIVER DISEASES THERAPEUTICS MARKET 3.5.1 BARGAINING POWER OF SUPPLIERS 3.5.2 BARGAINING POWER OF BUYERS 3.5.3 THREAT OF NEW ENTRANTS 3.5.4 THREAT OF SUBSTITUTES 3.5.5 COMPETITIVE RIVALRYCHAPTER 4 LIVER DISEASES CLASSIFICATION AND THERAPY OPTIONS4.1 ALCOHOL INDUCED LIVER DISEASE 4.1.1 OVERVIEW 4.1.2 EPIDEMIOLOGY 4.1.3 ETIOLOGY 4.1.4 SYMPTOMS 4.1.5 PATHOPHYSIOLOGY 4.1.6 TREATMENT PATTERN AND THERAPY OPTIONS 4.1.6.1 Anabolic Steroids 4.1.6.2 Alcohol Abuse Drugs4.2 AUTOIMMUNE LIVER DISORDER 4.2.1 AUTOIMMUNE HEPATITIS (AIH)Browse Report: http://www.transparencymarketresearch.com/liver-diseases-therapeutics.html
  • 4. 4.2.1.1 OVERVIEW 4.2.1.2 EPIDEMIOLOGY 4.2.1.3 ETIOLOGY 4.2.1.4 SYMPTOMS 4.2.1.5 PATHOPHYSIOLOGY 4.2.1.6 TREATMENT PATTERN AND THERAPY OPTIONS 4.2.1.6.1 Antimetabolites 4.2.1.6.2 Corticosteroids4.3 HEPATOCELLULAR CARCINOMA 4.3.1 OVERVIEW 4.3.2 EPIDEMIOLOGY 4.3.3 ETIOLOGY 4.3.4 SYMPTOMS 4.3.5 PATHOPHYSIOLOGY 4.3.6 TREATMENT PATTERN AND THERAPY OPTIONS 4.3.6.1 Chemotherapy 4.3.6.2 Targeted Therapy4.4 NON-ALCOHOLIC FATTY LIVER DISEASE 4.4.1 OVERVIEW 4.4.2 EPIDEMIOLOGY 4.4.3 ETIOLOGY 4.4.4 SYMPTOMS 4.4.5 PATHOPHYSIOLOGY 4.4.6 TREATMENT PATTERN AND THERAPY OPTIONS 4.4.6.1 Gallstone solubilising drugs4.5 VIRAL/HEPATITIS LIVER DISORDER 4.5.1 HEPATITIS A
  • 5. Browse Report: http://www.transparencymarketresearch.com/liver-diseases-therapeutics.html 4.5.1.1 OVERVIEW 4.5.1.2 EPIDEMIOLOGY 4.5.1.3 ETIOLOGY 4.5.1.4 SYMPTOMS 4.5.1.5 PATHOPHYSIOLOGY 4.5.1.6 TREATMENT PATTERN AND THERAPY OPTIONS 4.5.1.6.1 Vaccines 4.5.1.6.2 Immunoglobulins 4.5.2 HEPATITIS B 4.5.2.1 OVERVIEW 4.5.2.2 EPIDEMIOLOGY 4.5.2.3 ETIOLOGY 4.5.2.4 SYMPTOMS 4.5.2.5 PATHOPHYSIOLOGY 4.5.2.6 TREATMENT PATTERN AND THERAPY OPTIONS 4.5.2.6.1 Antiviral drugs 4.5.2.6.2 Immunoglobulins 4.5.2.6.3 Vaccines 4.5.3 HEPATITIS C 4.5.3.1 OVERVIEW 4.5.3.2 EPIDEMIOLOGY 4.5.3.3 ETIOLOGY 4.5.3.4 SYMPTOMS 4.5.3.5 PATHOPHYSIOLOGY
  • 6. 4.5.3.6 TREATMENT PATTERN AND THERAPY OPTIONS 4.5.3.6.1 Antiviral drugs 4.5.4 HEPATITIS D 4.5.4.1 OVERVIEW 4.5.4.2 EPIDEMIOLOGY 4.5.4.3 ETIOLOGY 4.5.4.4 SYMPTOMS 4.5.4.5 PATHOPHYSIOLOGY 4.5.4.6 TREATMENT PATTERN AND THERAPY OPTIONS 4.5.5 HEPATITIS E 4.5.5.1 OVERVIEW 4.5.5.2 EPIDEMIOLOGY 4.5.5.3 ETIOLOGY 4.5.5.4 SYMPTOMS 4.5.5.5 PATHOPHYSIOLOGY 4.5.5.6 TREATMENT PATTERN AND THERAPY OPTIONSCHAPTER 5 LIVER DISEASES THERAPEUTICS MARKET, BY DRUG CLASS5.1 IMMUNOSUPPRESSANTS 5.1.1 GLOBAL IMMUNOSUPPRESSANTS MARKET FOR LIVER DISEASE THERAPEUTICS,2010 – 2018 (USD MILLION)5.2 CHEMOTHERAPY DRUGS 5.2.1 GLOBAL CHEMOTHERAPY DRUGS MARKET FOR LIVER DISEASE THERAPEUTICS,2010 – 2018 (USD MILLION)5.3 TARGETED THERAPY DRUGS 5.3.1 GLOBAL TARGETED THERAPY MARKET FOR LIVER DISEASE THERAPEUTICS, 2010– 2018 (USD MILLION)5.4 VACCINES
  • 7. 5.4.1 GLOBAL VACCINES MARKET FOR LIVER DISEASE THERAPEUTICS, 2010 – 2018(USD MILLION)5.5 ANTI-VIRAL DRUGS 5.5.1 GLOBAL ANTI-VIRAL DRUGS MARKET FOR LIVER DISEASE THERAPEUTICS, 2010– 2018 (USD MILLION)5.6 IMMUNOGLOBULINS 5.6.1 GLOBAL IMMUNOGLOBULINS MARKET FOR LIVER DISEASE THERAPEUTICS, 2010– 2018 (USD MILLION)5.7 CORTICOSTERIODS 5.7.1 GLOBAL CORTICOSTERIODS MARKET FOR LIVER DISEASE THERAPEUTICS, 2010– 2018 (USD MILLION)CHAPTER 6 COMPETITIVE LANDSCAPE6.1 MARKET SHARE OF KEY PLAYERS IN LIVER DISEASES THERAPEUTICS MARKET BY DRUGCLASS 6.1.1 MARKET SHARE OF KEY PLAYERS FOR IMMUNOSUPPRESSANTS MARKET FORLIVER DISEASES 6.1.2 MARKET SHARE OF KEY PLAYERS FOR VACCINES MARKET FOR LIVER DISEASES 6.1.3 MARKET SHARE OF KEY PLAYERS FOR ANTI-VIRAL DRUGS MARKET FOR LIVERDISEASES 6.1.4 MARKET SHARE OF KEY PLAYERS FOR TARGETED THERAPY FOR LIVER DISEASES 6.1.5 NEW ENTRANTS (PHASE III) 6.1.6 COMPETITIVE STRATEGY BY KEY PLAYERS 6.1.6.1 Investments in R&D and clinical studies 6.1.6.2 Entering the emerging economies 6.1.6.3 Investing in different segments of the market 6.1.7 COMPETITIVE STRATEGY BY NEW ENTRANTS 6.1.8 AGREEMENTS AND COLLABORATIONS
  • 8. Browse Report: http://www.transparencymarketresearch.com/liver-diseases-therapeutics.htmlCHAPTER 7 RECOMMENDATIONS7.1 MARKET STRATEGY FOR SUCCESS7.2 BARRIERS TO BE CONSIDEREDCHAPTER 8 COMPANY PROFILES8.1 ABBOTT LABORATORIES 8.1.1 COMPANY OVERVIEW 8.1.2 FINANCIAL OVERVIEW 8.1.3 BUSINESS STRATEGIES 8.1.3.1 Significant R&D investments for new products development 8.1.3.2 Investing in emerging markets 8.1.3.3 Conducting clinical trials 8.1.4 PRODUCT PORTFOLIO 8.1.5 RECENT DEVELOPMENTS8.2 ASTELLAS PHARMA INC. 8.2.1 COMPANY OVERVIEW 8.2.2 FINANCIAL OVERVIEW 8.2.3 BUSINESS STRATEGIES 8.2.3.1 Investing in emerging economies 8.2.3.2 Investing in research and development 8.2.4 PRODUCT PORTFOLIO 8.2.5 RECENT DEVELOPMENTS8.3 BRISTOL-MYERS SQUIBB 8.3.1 COMPANY OVERVIEW
  • 9. 8.3.2 FINANCIAL OVERVIEW 8.3.3 BUSINESS STRATEGIES 8.3.3.1 Mergers, acquisitiosn and strategic development 8.3.3.2 Investing in research and development 8.3.4 PRODUCT PORTFOLIO 8.3.5 RECENT DEVELOPMENTS8.4 GILEAD SCIENCES 8.4.1 COMPANY OVERVIEW 8.4.2 FINANCIAL OVERVIEW 8.4.3 BUSINESS STRATEGIES 8.4.3.1 Innovative new products 8.4.3.2 Investing in research and development 8.4.4 PRODUCT PORTFOLIO 8.4.5 RECENT DEVELOPMENTS8.5 GLAXOSMITHKLINE PLC 8.5.1 COMPANY OVERVIEW 8.5.2 FINANCIAL OVERVIEW 8.5.3 BUSINESS STRATEGIES 8.5.3.1 Research and development investments 8.5.3.2 Delivering new products 8.5.4 PRODUCT PORTFOLIO 8.5.5 RECENT DEVELOPMENTS8.6 F. HOFFMANN-LA ROCHE LTD 8.6.1 COMPANY OVERVIEW 8.6.2 FINANCIAL OVERVIEW 8.6.3 BUSINESS STRATEGIES 8.6.3.1 Strategic alliance initiative
  • 10. 8.6.3.2 Investing in research and development 8.6.4 PRODUCT PORTFOLIO 8.6.5 RECENT DEVELOPMENTS8.7 MERCK & CO. INC 8.7.1 COMPANY OVERVIEW 8.7.2 FINANCIAL OVERVIEW 8.7.3 BUSINESS STRATEGIES 8.7.3.1 R&D initiatives 8.7.3.2 Strategic alliance 8.7.3.3 Corporate social responsibility and awareness 8.7.4 PRODUCT PORTFOLIO 8.7.5 RECENT DEVELOPMENTS8.8 NOVARTIS AG 8.8.1 COMPANY OVERVIEW 8.8.2 FINANCIAL OVERVIEW 8.8.3 BUSINESS STRATEGIES 8.8.3.1 Strategic alliance 8.8.3.2 Investing in research and development 8.8.4 PRODUCT PORTFOLIO 8.8.5 RECENT DEVELOPMENTS8.9 SANOFI S.A 8.9.1 COMPANY OVERVIEW 8.9.2 FINANCIAL OVERVIEW 8.9.3 BUSINESS STRATEGIES 8.9.3.1 Business Diversification 8.9.3.2 Research and development initiative 8.9.4 PRODUCT PORTFOLIO
  • 11. 8.9.5 RECENT DEVELOPMENTS8.10 PFIZER INC. 8.10.1 COMPANY OVERVIEW 8.10.2 FINANCIAL OVERVIEW 8.10.3 BUSINESS STRATEGIES 8.10.3.1 Investing in research and development 8.10.4 PRODUCT PORTFOLIO 8.10.5 RECENT DEVELOPMENTS8.11 TAKEDA PHARMACEUTICAL 8.11.1 COMPANY OVERVIEW 8.11.2 FINANCIAL OVERVIEW 8.11.3 BUSINESS STRATEGIES 8.11.3.1 Investing in emerging economies 8.11.3.2 Investing in research and development 8.11.4 PRODUCT PORTFOLIO 8.11.5 RECENT DEVELOPMENTS8.12 VALEANT PHARMACEUTICALS 8.12.1 COMPANY OVERVIEW 8.12.2 FINANCIAL OVERVIEW 8.12.3 BUSINESS STRATEGIES 8.12.3.1 Strategic alliance 8.12.4 PRODUCT PORTFOLIO 8.12.5 RECENT DEVELOPMENTS8.13 WATSON PHARMACEUTICALS, INC. 8.13.1 COMPANY OVERVIEW 8.13.2 FINANCIAL OVERVIEW 8.13.3 BUSINESS STRATEGIES
  • 12. 8.13.3.1 Investing in generic and biosimilar segments 8.13.3.2 Investing in research and development 8.13.4 PRODUCT PORTFOLIO 8.13.5 RECENT DEVELOPMENTSAbout Us:Transparency Market Research is a market intelligence company providing global businessinformation reports and services. Our exclusive blend of quantitative forecasting and trendsanalysis provides forward-looking insight for thousands of decision makers.We are privileged with highly experienced team of Analysts, Researchers and Consultants,who use proprietary data sources and various tools and techniques to gather, and analyzeinformation. Our business offerings represent the latest and the most reliable informationindispensable for businesses to sustain a competitive edge.Contact:Transparency Market Research90 State Street,Suite 700,AlbanyNY - 12207United StatesTel: +1-518-618-1030USA - Canada Toll Free 866-552-3453Email: sales@transparencymarketresearch.comWebsite: http://www.transparencymarketresearch.com/